Fleckenstein A, Fleckenstein-Grün G
Arzneimittelforschung. 1977;27(3a):736-42.
Ca-antagonistic drugs increase cardiac oxygen supply by a coronary vasodilator action whilst they simultaneously lower myocardial oxygen demand. The latter drug effect is due to a decrease in cardiac contractile energy expenditure both directly (restriction of myocardial contractility) and indirectly (reduction of arterial blood pressure resulting from systemic vasodilation). In coronary disease all these factors can contribute to an improvement of the disturbed myocardial energy balance. As to the coronary vasodilator action of Ca-antagonistic drugs in particular, it is important to note that they readily relax the smooth musculature of the major extramural stem arteries where most of the occlusive atherosclerotic intima processes (about 95%) are located. In contrast, other coronary vasodilators such as adenosine, dipyridamole, chromonar, lidoflazine, theophylline, which lack Ca-antagonistic properties, are primarily acting on the small intramural resistance vessels of the heart whereas vascular smooth musculature originating from the major extramural arteries is less affected. Therefore, in elderly atherosclerotic patients the possible risk of glycoside-induced vasoconstriction in extramural coronary stem arteries (and also in arteries of systemic circulation) can be sufficiently eliminated only with the help of Ca-antagonists.
钙拮抗药通过冠状动脉扩张作用增加心脏氧供,同时降低心肌氧需求。后一种药物作用是由于心脏收缩能量消耗直接减少(心肌收缩力受限)和间接减少(全身血管扩张导致动脉血压降低)。在冠心病中,所有这些因素都有助于改善紊乱的心肌能量平衡。关于钙拮抗药的冠状动脉扩张作用,尤其要注意的是,它们能使大部分闭塞性动脉粥样硬化内膜病变(约95%)所在的主要壁外主干动脉的平滑肌组织容易松弛。相比之下,其他缺乏钙拮抗特性的冠状动脉扩张药,如腺苷、双嘧达莫、色满卡林、利多氟嗪、茶碱,主要作用于心脏的小壁内阻力血管,而来自主要壁外动脉的血管平滑肌组织受影响较小。因此,在老年动脉粥样硬化患者中,只有借助钙拮抗剂才能充分消除糖苷类药物引起的壁外冠状动脉主干动脉(以及体循环动脉)血管收缩的潜在风险。